Figure 1
From: Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models
Combination of HSV1716 with anti-PD-1 antibody significantly prolongs survival in the male M3-9-M tumor model. (a) Schematic illustrates the dosing regimens for mice bearing subcutaneous M3-9-M tumors. Male C57BL/6 mice were implanted with 5 × 106 M3-9-M cells subcutaneously and treated with three intratumoral (i.tu.) injections of 108 pfu HSV1716 followed by intraperitoneal (i.p.) injections of anti-PD-1 antibody. (b) Tumor volumes of mice treated with anti-PD-1 (green lines; n = 6), HSV1716 (blue lines; n = 6) and combined therapy (red lines; n = 7) were measured twice a week and plotted individually against tumor volumes recorded for control mice (black lines; n = 7). (c) Kaplan-Meier survival curves for each treatment group demonstrate the improved efficacy of combining PD-1 blockade with HSV1716 virotherapy. Survival data were evaluated for statistical significance with Log-rank Mantel-Cox test.
